Light-activated therapy may change skin at molecular level

October 20, 2008

Photodynamic therapy--which involves a light-activated medication and exposure to a light source--appears to produce changes at the molecular level in aging skin, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals. These changes are consistent with increased collagen production and improved appearance of the skin.

"The deleterious effects of exposure of the skin to UV irradiation are well established," the authors write as background information in the article. "Alternatively, several visible and infrared lasers and light sources have been reported to produce various positive changes in the clinical and histologic [microscopic] appearance of the skin. In recent years, the concept of employing a photosensitizing compound to enhance the effects of some light-based therapies has been espoused."

For aesthetic treatments, this type of photodynamic therapy typically involves application of a topical medication, such as 5-aminolevulinic acid (5-ALA), that is activated by exposure to light. Jeffrey S. Orringer, M.D., and colleagues at the University of Michigan Medical School, Ann Arbor, studied this treatment in 25 adults age 54 to 83 with sun-damaged skin on their forearms. Before treatment, the degree of skin damage was rated and a biopsy (tissue sample) was taken from the forearm. A solution containing 5-ALA was applied to the treatment site and left on for three hours; the skin was then washed with cleanser and treated with a pulsed-dye laser. Participants returned for re-examination and to provide additional biopsy samples four to five times during the six months following treatment.

After photodynamic therapy, tissue samples demonstrated a five-fold increase in levels of Ki67, a protein thought to play a fundamental role in the growth and development of new skin cells. The epidermis (skin's outer layer) increased in thickness 1.4-fold. Levels of enzymes and other compounds associated with the production of collagen, the main structural protein in the skin, also were increased.

"Photodynamic therapy with the specific treatment regimen employed produces statistically significant quantitative cutaneous molecular changes (e.g., production of types I and III collagen) that are associated with improved appearance of the skin," the authors conclude. When compared with previous data regarding the effectiveness of pulsed-dye laser therapy alone, these results suggest that using a photosensitive compound such as 5-ALA enhances changes in the skin.

"Although our molecular measurements cannot yet precisely predict clinical outcomes for a single given patient, taken together they are very much in keeping with the bulk of the clinical literature and thus lend substantial support to the conclusions reached by other researchers who have published purely clinically oriented work in this field," the authors conclude. "We believe that the quantitative amount of dermal repair and regeneration induced by a specific therapeutic intervention very likely underlies the degree of clinical rejuvenation produced. Thus, it is our hope that, with further development, our working molecular model may one day be used to predict the clinical value of new technologies in aesthetic dermatology."
-end-
(Arch Dermatol. 2008;144[10]:1296-1302. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This study was funded in its entirety by the Human Appearance Research Program (HARP) of the Department of Dermatology, University of Michigan. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Biopsy Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Liquid biopsy faster than tissue biopsy, improves time to treat
A pilot study comparing the effects of a liquid biopsy with tissue-based test showed that liquid biopsy turn-around time for results was approximately 10 days faster than the tissue biopsy, according to research presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.

Study focuses on a different kind of liquid biopsy to detect cancer
In a study published August 13, 2020, in Cell by a team of collaborators from Memorial Sloan Kettering and Weill Cornell Medicine, researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

Chip for liquid biopsy will help to detect prostate cancer
Researchers of Sechenov University together with their colleagues from Australia used the microfluidics technology to develop a device able to isolate cancer cells from urine of patients with prostate cancer.

Hybrid microscope could bring digital biopsy to the clinic
By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

Sentinel lymph node biopsy has no benefits for stage zero breast cancer
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.

CNIO researchers assess melanoma progression with a new liquid biopsy technique
Analysis of extracellular vesicles and circulating DNA from fluid obtained from the drainage implanted after surgery, normally disposed of as medical waste, detects melanoma patients with risk of recurrence and may help doctors decide who should undergo adjuvant therapy The new technique might change the way melanoma patients are followed up.

Contrast-enhanced MRI provides useful findings in discordant core biopsy management
An essential part of breast intervention is the process of assessing concordance between imaging findings and core biopsy results.

3D mammography significantly reduces breast biopsy rates
The use of digital breast tomosynthesis, also known as 3D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study.

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Read More: Biopsy News and Biopsy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.